Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

NASDAQ:LGND  
150.73
-6.19 (-3.94%)
Equity Financing / Related

Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led By Perceptive Xontogeny Ventures Fund Ii

Published: 11/15/2021 17:21 GMT
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B (LGND) - Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund Ii.
Sermonix Pharmaceuticals - Fred Callori and Ben Askew, Partners in Pxv Fund, Were Appointed to Sermonix Board of Directors.